Company news
Oncodesign Precision Medicine S.A. news in 2025
Oncodesign Precision Medicine S.A.'s news releases, calls and decks from 2025, newest first.
Oncodesign Precision Medicine and Navigo Proteins Announce the End of Their Collaboration in the Development of Radiotheranostics
December 29, 2025
OPM Obtains Development Grants From the Bourgogne Franche-Comté Region
October 14, 2025
OPM Publishes Its 2025 Half-Yearly Report
October 9, 2025
OPM Integrated Into the LRRK2 Investigative Therapeutics Exchange Program From the Michael J. Fox Foundation for Parkinson’s Research
September 25, 2025
OPM Announces Its 2025 Half-Year Financial Results and Provides an Update on Its Clinical Developments and Financial Position
July 31, 2025
Oncodesign Precision Medicine Announces Equity Financing of up to 5 Million Euros
April 17, 2025
Oncodesign Precision Medicine: OPM announces equity financing of up to 5 million euros
April 17, 2025
OPM Announces Its 2024 Annual Results and Clinical Developments
April 3, 2025
Oncodesign Precision Medicine: OPM) Announces Protocol Submission for its Phase 1b/2a Study, REVERT for OPM 101 in Combination with Pembrolizumab in Patients with Advanced Melanoma Resistant to Anti PD1
March 24, 2025